Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415467 · ClinicalTrials.gov registry record · Phase 4
Treatment of Resectable Malignant Brain Tumors
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00415467: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT00415467 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415467, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goals of this study are to evaluate each of the following items: 1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS 2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® Radiation Therapy System (RTS). 3. Incidence of serious adverse events in patients treated with GliaSite RTS
Primary Outcome
Time to recurrence of brain tumor determined for each patient from the time at the end date of brachytherapy with the GliaSite RTS until the date of documented brain tumor recurrence.
Interventions
- DEVICE GliaSite Radiation Therapy System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Why NCT00415467 stopped before completion
NCT00415467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which GliaSite Radiation Therapy System is the first listed.
NCT00415467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00415467 about?
NCT00415467 is a clinical study titled "Treatment of Resectable Malignant Brain Tumors". The goals of this study are to evaluate each of the following items: 1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS 2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® ...
What is the current status of trial NCT00415467?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00415467?
The interventions under investigation include: GliaSite Radiation Therapy System (DEVICE).
Who is sponsoring clinical trial NCT00415467?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00415467's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia